64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)

Clinical trial NCT04726033 · COMPLETED

Trial details

NCT number: NCT04726033
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Metastatic Prostate Cancer

Start date: 2021-08-04
Primary completion: 2023-12-30
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.